Novel PXDN biallelic variants in patients with microphthalmia and anterior segment dysgenesis.


Journal

Journal of human genetics
ISSN: 1435-232X
Titre abrégé: J Hum Genet
Pays: England
ID NLM: 9808008

Informations de publication

Date de publication:
May 2020
Historique:
received: 24 07 2019
accepted: 11 01 2020
revised: 08 01 2020
pubmed: 6 2 2020
medline: 18 12 2020
entrez: 5 2 2020
Statut: ppublish

Résumé

Microphthalmia, anophthalmia, and anterior segment dysgenesis are severe ocular developmental defects. There is a wide genetic heterogeneity leading to these ocular malformations. By using whole genome, exome and targeted sequencing in patients with ocular developmental anomalies, six biallelic pathogenic variants (including five novel variants) were identified in the PXDN gene in four families with microphthalmia and anterior segment dysgenesis. Only 11 different mutations (11 families) have been described in this gene to date. The phenotype of these patients is variable in severity, ranging from cataract and developmental glaucoma to complex microphthalmia. Interestingly, two unrelated patients of our series presented with an ocular phenotype including aniridia and microspherophakia. However, despite various phenotypic presentations and types of mutations, no genotype-phenotype correlation could be made. Thus, this work improves our knowledge of the recessive phenotype associated with biallelic variants in this gene and highlights the importance of screening PXDN in patients with anterior segment dysgenesis with or without microphthalmia.

Identifiants

pubmed: 32015378
doi: 10.1038/s10038-020-0726-x
pii: 10.1038/s10038-020-0726-x
doi:

Substances chimiques

PXDN protein, human EC 1.11.1.-
Peroxidases EC 1.11.1.-

Types de publication

Case Reports Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-491

Références

Plaisancie J, Ceroni F, Holt R, Zazo Seco C, Calvas P, Chassaing N, et al. Genetics of anophthalmia and microphthalmia. Part 1: non-syndromic anophthalmia/microphthalmia. Hum Genet. 2019;138:799–830.
doi: 10.1007/s00439-019-01977-y
Reis LM, Semina EV. Genetics of anterior segment dysgenesis disorders. Curr Opin Ophthalmol. 2011;22:314–24.
doi: 10.1097/ICU.0b013e328349412b
Khan K, Rudkin A, Parry DA, Burdon KP, McKibbin M, Logan CV, et al. Homozygous mutations in PXDN cause congenital cataract, corneal opacity, and developmental glaucoma. Am J Hum Genet. 2011;89:464–73.
doi: 10.1016/j.ajhg.2011.08.005
Balci TB, Hartley T, Xi Y, Dyment DA, Beaulieu CL, Bernier FP, et al. Debunking Occam’s razor: diagnosing multiple genetic diseases in families by whole-exome sequencing. Clin Genet. 2017;92:281–9.
doi: 10.1111/cge.12987
Choi A, Lao R, Ling-Fung Tang P, Wan E, Mayer W, Bardakjian T, et al. Novel mutations in PXDN cause microphthalmia and anterior segment dysgenesis. Eur J Hum Genet. 2015;23:337–41.
doi: 10.1038/ejhg.2014.119
Micheal S, Siddiqui SN, Zafar SN, Iqbal A, Khan MI, den Hollander AI. Identification of novel variants in LTBP2 and PXDN using whole-exome sequencing in developmental and congenital glaucoma. PLoS One. 2016;11:e0159259.
doi: 10.1371/journal.pone.0159259
Patel N, Khan AO, Alsahli S, Abdel-Salam G, Nowilaty SR, Mansour AM, et al. Genetic investigation of 93 families with microphthalmia or posterior microphthalmos. Clin Genet. 2018;93:1210–22.
doi: 10.1111/cge.13239
Heather JM, Chain B. The sequence of sequencers: the history of sequencing DNA. Genomics. 2016;107:1–8.
doi: 10.1016/j.ygeno.2015.11.003
Cavodeassi F, Creuzet S, Etchevers HC. The hedgehog pathway and ocular developmental anomalies. Hum Genet. 2018;138:917–36.
doi: 10.1007/s00439-018-1918-8
Plaisancie J, Ragge NK, Dollfus H, Kaplan J, Lehalle D, Francannet C, et al. FOXE3 mutations: genotype-phenotype correlations. Clin Genet. 2018;93:837–45.
doi: 10.1111/cge.13177
Zazo Seco C, Plaisancie J, Lupasco T, Michot C, Pechmeja J, Delanne J, et al. Identification of PITX3 mutations in individuals with various ocular developmental defects. Ophthalmic Genet. 2018;39:314–20.
doi: 10.1080/13816810.2018.1430243
Bhave G, Cummings CF, Vanacore RM, Kumagai-Cresse C, Ero-Tolliver IA, Rafi M, et al. Peroxidasin forms sulfilimine chemical bonds using hypohalous acids in tissue genesis. Nat Chem Biol. 2012;8:784–90.
doi: 10.1038/nchembio.1038
Yan X, Sabrautzki S, Horsch M, Fuchs H, Gailus-Durner V, Beckers J, et al. Peroxidasin is essential for eye development in the mouse. Hum Mol Genet. 2014;23:5597–614.
doi: 10.1093/hmg/ddu274
Mao M, Kiss M, Ou Y, Gould DB. Genetic dissection of anterior segment dysgenesis caused by a Col4a1 mutation in mouse. Dis Models Mech. 2017;10:475–85.
doi: 10.1242/dmm.027888
Deml B, Reis LM, Maheshwari M, Griffis C, Bick D, Semina EV. Whole exome analysis identifies dominant COL4A1 mutations in patients with complex ocular phenotypes involving microphthalmia. Clin Genet. 2014;86:475–81.
doi: 10.1111/cge.12379
Graw J. Eye development. Curr Top Dev Biol. 2010;90:343–86.
doi: 10.1016/S0070-2153(10)90010-0
Medina-Martinez O, Jamrich M. Foxe view of lens development and disease. Development. 2007;134:1455–63.
doi: 10.1242/dev.000117
Yan XH, Li DL, Cheng HB. Generation of a novel peroxidasin knockout mouse. Investig Ophthalmol Vis Sci. 2018;59:325.
Sitole BN, Mavri-Damelin D. Peroxidasin is regulated by the epithelial-mesenchymal transition master transcription factor snail. Gene. 2018;646:195–202.
doi: 10.1016/j.gene.2018.01.011
Liskova P, Dudakova L, Evans CJ, Rojas Lopez KE, Pontikos N, Athanasiou D, et al. Ectopic GRHL2 expression due to non-coding mutations promotes cell state transition and causes posterior polymorphous corneal dystrophy 4. Am J Hum Genet. 2018;102:447–59.
doi: 10.1016/j.ajhg.2018.02.002

Auteurs

Celia Zazo-Seco (C)

UDEAR, UMR 1056 Inserm-Université de Toulouse, Toulouse, France.

Julie Plaisancié (J)

UDEAR, UMR 1056 Inserm-Université de Toulouse, Toulouse, France.
Department of Medical Genetics, CHU Toulouse, Toulouse, France.

Pierre Bitoun (P)

SIDVA 91, Ophthalmic Genetics, Juvisy-sur-Orge, France.

Marta Corton (M)

Department of Genetics, Fundación Jiménez Díaz University Hospital, CIBERER, (IIS-FJD, UAM), Madrid, Spain.

Ana Arteche (A)

Department of Genetics, Fundación Jiménez Díaz University Hospital, CIBERER, (IIS-FJD, UAM), Madrid, Spain.

Carmen Ayuso (C)

Department of Genetics, Fundación Jiménez Díaz University Hospital, CIBERER, (IIS-FJD, UAM), Madrid, Spain.

Adele Schneider (A)

Division of Medical Genetics, Einstein Healthcare Network, Philadelphia, PA, USA.

Dimitra Zafeiropoulou (D)

Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands.

Christian Gilissen (C)

Department of Human Genetics, Radboud University Medical Centre, Nijmegen, The Netherlands.

Olivier Roche (O)

Department of Ophthalmology, IHU Necker-Enfants-Malades, Paris-Descartes University, Paris, France.

Felix Frémont (F)

Department of Ophthalmology, CHU Toulouse, Toulouse, France.

Patrick Calvas (P)

UDEAR, UMR 1056 Inserm-Université de Toulouse, Toulouse, France.
Department of Medical Genetics, CHU Toulouse, Toulouse, France.

Anne Slavotinek (A)

Department of Pediatrics, University of California, San Francisco, CA, USA.

Nicola Ragge (N)

Department of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, UK.
West Midlands Regional Genetics Service and Birmingham Health Partners Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK.

Nicolas Chassaing (N)

UDEAR, UMR 1056 Inserm-Université de Toulouse, Toulouse, France. chassaing.n@chu-toulouse.fr.
Department of Medical Genetics, CHU Toulouse, Toulouse, France. chassaing.n@chu-toulouse.fr.
Génétique Médicale, Hôpital Purpan, 31300, Toulouse, France. chassaing.n@chu-toulouse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH